Compare Boston Scientific Corporation (BSX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ProShares Ultra Gold ETF — how do they compare? Boston Scientific Corporation trades at $42.71 (market cap $66.37B), while ProShares Ultra Gold ETF trades at $43.92. The key difference: ProShares Ultra Gold ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | UGL | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.14 | $85.62 |
52-Week Low | $42.63 | $33.59 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
UGL trades at $43.38, down 5.2% over 24 hours amid a bearish technical outlook with 19 sell signals versus 2 buys. The stock faces resistance at $44 and $45, with support at $43 and $42. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights gold market volatility, with prices influenced by Fed policy, inflation data, and geopolitical tensions, though UGL's direct exposure is not detailed.
The outlook remains cautious due to weak technical momentum and lack of financial data. Risks include gold price sensitivity to interest rates and macroeconomic shifts. Investors should await earnings reports for fundamental validation, as current analysis relies heavily on technical indicators and broader sector sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
